Clinical trials: Liver Cancer, Adult
Solid Tumors
Tabectedin to Treat Children and Adolescents With Cancer
Background: Trabectedin is an experimental drug that kills some cancer cells in the laboratory and in mice by interfering with genetic material (DNA) in cancer cells.
- Trial name
- NCT01453283
- Testing
- Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma.
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma
- Trial name
- NCT05602194
- Testing
- Biospecimen Collection, Calaspargase Pegol, Levocarnitine
- Where
- 228 sites in United States, Canada
- Volunteers
- 440 people
- Sponsor
- Children's Oncology Group
Hepatocellular Carcinoma
Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis
The purpose of this study is to assess the efficacy of Radiofrequency ablation (RFA) and percutaneous acetic acid ablation (PAI) in the management of small hepatocellular carcinoma (HCC) in patients of cirrhosis of liver.
- Trial name
- NCT01438437
- Testing
- PAI, RFA
- Where
- India
- Volunteers
- 54 people
- Sponsor
- All India Institute of Medical Sciences
Hepatocellular Carcinoma, Portal Vein Thrombosis
Surgical Outcome of HCC With Portal Vein Tumor Thrombosis on the Basis of Risk Scoring
The goal of this multicenter retrospective cohort study is to investigate the clinical outcomes and prognostic factors after hepatic resection in patients with HCC exhibiting PVTT, and to develop a prognostic index that can be…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Thrombosis, Prognosis
- Trial name
- NCT06005883
- Where
- South Korea
- Volunteers
- 332 people
- Sponsor
- Keimyung University Dongsan Medical Center
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed by surgery (unresectable).
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04380545
- Testing
- Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- PNeoVCA (NCT05269381)
- Testing
- Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic
Liver Tumours, Ultrasound
Standing Position Ultrasonography: Imaging Efficacy in Detecting Liver Diaphragmatic Dome Blind Area Lesions
Objective: To compare the detection efficacy of standing, supine, and left lateral decubitus ultrasonographic scanning for space-occupying lesions ≤3cm in the liver dome "blind area" and assess the feasibility of standing…
- Conditions
- Liver Tumours, Ultrasound, Position
- Trial name
- NCT07579533
- Where
- China
- Volunteers
- 95 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma
Predictors of Sorafenib Response in HCC
Evaluating the nutrition status of patients with advanced HCC who received sorafenib. Using the pretreatment nutrition status and quality of life as predictors to sorafenib response
- Trial name
- NCT05967429
- Testing
- The neutrophil-to- lymphocyte ratio, Prognostic nutrition index
- Volunteers
- 80 people
- Sponsor
- Sohag University
Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single…
- Conditions
- Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer
- Trial name
- ICEMELT (NCT04631731)
- Testing
- Blood screening, Tissue screening
- Where
- 2 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Western Sydney Local Health District
Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC.
- Trial name
- NCT02234986
- Testing
- ENMD-2076
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- CASI pharmaceuticals, Inc.
Fibrolamellar Hepatocellular Carcinoma (FLC)
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC…
- Trial name
- NCT04248569
- Testing
- DNAJB1-PRKACA peptide vaccine, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HepatoCellular Carcinoma
CHARM Hepatocellular Carcinoma MEA Study
Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the third reason for cancer-related death worldwide.
- Trial name
- NCT07650773
- Where
- 17 sites in Egypt, Kuwait and 5 more
- Volunteers
- 4,000 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma Non-resectable, Chemoembolization, Therapeutic
Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan
To evaluate efficacy and safety profile of DC bead® TACE in patients with hepatocellular carcinoma in Taiwan.
- Trial name
- SERENADE-T (NCT03283956)
- Testing
- Patient records
- Where
- Taiwan
- Volunteers
- 500 people
- Sponsor
- National Taiwan University Hospital
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors
RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less damage to normal tissue. PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating patients who have…
- Trial name
- NCT00006456
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Virginia Commonwealth University
Hepatocellular Carcinoma
Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC
Hepatocellular carcinoma (HCC) is the fifth most common and the third leading cause of death from cancer worldwide1 . Hepatectomy is still the main effective treatment for HCC accompanying with well-preserved cirrhosis when liver…
- Trial name
- NCT02535117
- Testing
- Laparoscopic Surgery(LS), RFA
- Volunteers
- 216 people
- Sponsor
- Sun Yat-sen University
Rupture, Spontaneous
A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular
Develop a new scoring system for HCC patients with tumor rupture.
- Trial name
- NCT03504358
- Testing
- Liver resection
- Volunteers
- 129 people
- Sponsor
- Huazhong University of Science and Technology
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital
Liver Tumors
Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study
The search for communicating veins (CVs) between adjacent hepatic veins (HVs) has drawn its rationale from living donor liver transplantation (LDLT).
- Trial name
- NCT00960609
- Testing
- Ultrasound guided liver resection
- Where
- Italy
- Sponsor
- University of Milan